
CCRN Stock Forecast & Price Target
CCRN Analyst Ratings
Bulls say
Cross Country Healthcare is poised for strong financial growth, with a proposed go-private transaction potentially boosting the company's stock performance. This potential acquisition by Knox Lane highlights the company's strong position in the healthcare staffing market and could lead to future synergies and growth opportunities. Along with positive internal business momentum and improved market conditions, Cross Country Healthcare is expected to see significant revenue growth and a potential rebound in industry demand.
Bears say
Cross Country Healthcare is expected to be acquired by Knox Lane for $13.25 per share, a 31% premium to its closing price on May 6,2026, and a 45% premium to the volume-weighted average trading price for the 90-day period ended May 6,2026. Despite recent investments and initiatives to improve quarterly adjusted EBITDA margins, the company's performance has been underwhelming, resulting in a depressed valuation that has attracted the interest of Knox Lane. The acquisition validates the potential of Cross Country's AI-powered digital platform and its turnaround potential, but the price paid by Knox Lane reflects a buyer taking advantage of a discounted valuation environment.
This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.
CCRN Analyst Forecast & Price Prediction
Start investing in CCRN
Order type
Buy in
Order amount
Est. shares
0 shares